Arrivent Biopharma, Inc., was incorporated under the laws of the State of Delaware on April 14, 2021. The company is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated drugs to address the unmet medical needs of cancer patients. The company seeks to leverage the team's deep drug development experience to maximize the potential of its lead development candidate furamotinib through approval and commercialization in patients with cancer, and to advance a range of new therapies, such as next-generation antibody drug conjugates, with an initial focus on solid tumors. 

AVBP

AVBP Profile